Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Breast Neoplasms × Ogivri × Clear all

Phase

Status

Completed 7 Recruiting 3 Terminated 2 Withdrawn 1 Unknown 1 Suspended 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Malignant Solid Neoplasm 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced Breast Carcinoma 1

Interventions

Paclitaxel 56 Letrozole 49 Fulvestrant 46 Trastuzumab 41 pembrolizumab 35 palbociclib 35 Carboplatin 34 Cyclophosphamide 31 Anastrozole 30 pertuzumab 29 Capecitabine 24 exemestane 21 abemaciclib 21 Tamoxifen 20 Radiotherapy 20 Docetaxel 19 olaparib 18 ribociclib 17 Epirubicin 17 Doxorubicin 16 Surveys and Questionnaires 15 Magnetic Resonance Spectroscopy 15 durvalumab 14 Exercise 14 Alpelisib 14 trastuzumab deruxtecan 13 130-nm albumin-bound paclitaxel 12 Mastectomy, Segmental 11 Goserelin 11 Gonadotropin-Releasing Hormone 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04425018 2025-11-18

MARGOT

Dana-Farber Cancer Institute

Phase 2 Active not recruiting

174 enrolled 19 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡